125 related articles for article (PubMed ID: 29658501)
1. [Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant].
Krupitsky EM; Zvartau EE; Blokhina EA; Verbitskaya EV; Wahlgren VY; Tsoy-Podosenin MV; Bushara NM; Burakov AM; Masalov DV; Romanova TN; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Sulimov GY; Pecoraro A; Woody G
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(1. Vyp. 2):26-33. PubMed ID: 29658501
[TBL] [Abstract][Full Text] [Related]
2. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Yaroslavtseva T; Pecoraro A; Woody G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):614-620. PubMed ID: 27436632
[TBL] [Abstract][Full Text] [Related]
3. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.
Hyman SM; Fox H; Hong KI; Doebrick C; Sinha R
Exp Clin Psychopharmacol; 2007 Apr; 15(2):134-43. PubMed ID: 17469937
[TBL] [Abstract][Full Text] [Related]
4. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
5. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
6. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.
Carroll KM; Nich C; Frankforter TL; Yip SW; Kiluk BD; DeVito EE; Sofuoglu M
Drug Alcohol Depend; 2018 Nov; 192():264-270. PubMed ID: 30300800
[TBL] [Abstract][Full Text] [Related]
7. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
8. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
[TBL] [Abstract][Full Text] [Related]
9. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
[TBL] [Abstract][Full Text] [Related]
10. Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial.
Moosavyzadeh A; Mokri A; Ghaffari F; Faghihzadeh S; Azizi H; Jafari Hajati R; Naseri M
J Altern Complement Med; 2020 May; 26(5):376-383. PubMed ID: 32109133
[No Abstract] [Full Text] [Related]
11. Does naltrexone affect craving in abstinent opioid-dependent patients?
Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
[TBL] [Abstract][Full Text] [Related]
12. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
13. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
[TBL] [Abstract][Full Text] [Related]
14. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
15. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
16. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
17. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
18. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
[TBL] [Abstract][Full Text] [Related]
19. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
20. Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.
Lim AC; Grodin EN; Green R; Venegas A; Meredith LR; Courtney KE; Moallem NR; Sayegh P; London ED; Ray LA
Am J Drug Alcohol Abuse; 2020 Sep; 46(5):565-576. PubMed ID: 32343625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
